Table 2. Univariate conditional logistic regression analysis of risk factors for Stenotrophomonas maltophilia bacteremia compared to Pseudomonas aeruginosa bacteremia.
| S. maltophilia | P. aeruginosa | OR (95%CI) | P | |
|---|---|---|---|---|
| Variable | (n = 30) | (n = 30) | ||
| Central venous catheter | 22 (73.3) | 21 (70.0) | 1.25 (0.33–5.05) | 0.739 |
| Artificial products other than CVC | 22 (73.3) | 11 (36.7) | 4.67 (1.52–20.24) | 0.016 |
| Neutropenia a | 12 (40.0) | 15 (50.0) | 0.25 (0.01–1.69) | 0.215 |
| Persistent neutropenia b | 9 (30.0) | 5 (16.7) | 2.33 (0.65–10.83) | 0.22 |
| Prolonged hospitalization of > 30 days | 21 (70.0) | 17 (56.7) | 1.8 (0.62–5.86) | 0.292 |
| ICU stay before infection | 11 (36.7) | 3 (10.0) | 5.0 (1.32–32.53) | 0.038 |
| Chemotherapy within 30 days | 11 (36.7) | 12 (40.0) | 0.8 (0.20–3.02) | 0.739 |
| Transplantation within 30 days | 8 (26.7) | 5 (16.7) | 1.75 (0.53–6.68) | 0.372 |
| Previous antimicrobial therapy | ||||
| Carbapenems | 22 (73.3) | 16 (53.3) | 2.2 (0.80–6.98) | 0.144 |
| Anti-MRSAs c | 19 (63.3) | 7 (23.3) | 3.4 (1.34–10.34) | 0.016 |
| Antipseudomonal cephalosporins | 11 (36.7) | 6 (20.0) | 2.67 (0.77–12.17) | 0.148 |
| Fluoroquinolones | 12 (40.0) | 8 (26.7) | 1.67 (0.62–4.90) | 0.323 |
| Aminoglycosides | 5 (16.7) | 5 (16.7) | 1.0 (0.19–5.40) | 1 |
| TMP-SMX | 10 (33.3) | 14 (46.7) | 0.5 (0.13–1.59) | 0.258 |
| Minocycline | 4 (13.3) | 2 (6.7) | 2.0 (0.39–14.42) | 0.424 |
Data are no. (%) of patients, unless indicated otheriwse.
aNeutropenia was defined as an absolute neutrophil count of < 100 cells/mm3 at the onset of bacteremia.
bPersistent neutropenia was defined as an episode in which a neutrophil count <100/mm3 persisted more than 2 weeks before the onset.
cAnti-MRSAs included glycopeptides, linezolid, and daptomycin.
OR, odds ratio; CI, confidence interval; CVC, central venous catheter; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; TMP-SMX, trimethoprim-sulfamethoxazole